11.07.13
Sinovac Biotech Ltd., a China-based vaccine manufacturer, has been selected by the Jiangsu Centers for Disease Control and Prevention (Jiangsu CDC) to supply its inactivated hepatitis A vaccine, Healive, under the Expanded Program of Immunization (EPI) to the pediatric population in Jiangsu Province. Sinovac is one of two selected manufacturers, and will supply 900,000 doses of Healive to Jiangsu province. The total volume includes as many as 1.8 million doses.
Healive is the first inactivated hepatitis A vaccine developed, produced and marketed by a China-based manufacturer. It was launched in 2002 in China and is currently available in adult and pediatric dosage forms.
Dr. Weidong Yin, chairman, president and chief executive officer of Sinovac, said, "We are pleased to be selected once again by the Jiangsu CDC as one of the two suppliers of inactivated hepatitis A vaccine pursuant to the tender for the 2014 EPI. We are advancing our strategy to collaborate with the government agencies to provide top-quality vaccines to prevent and control diseases in China and beyond."
Healive is the first inactivated hepatitis A vaccine developed, produced and marketed by a China-based manufacturer. It was launched in 2002 in China and is currently available in adult and pediatric dosage forms.
Dr. Weidong Yin, chairman, president and chief executive officer of Sinovac, said, "We are pleased to be selected once again by the Jiangsu CDC as one of the two suppliers of inactivated hepatitis A vaccine pursuant to the tender for the 2014 EPI. We are advancing our strategy to collaborate with the government agencies to provide top-quality vaccines to prevent and control diseases in China and beyond."